Rachael Craig’s Post

Big pharma has gotten serious about TechBio and AI drug discovery, increasing their partnerships and investments 💊 We analyzed nine big pharma: Merck, Novo Nordisk, AstraZeneca, Bayer, Bristol Myers Squibb, Sanofi, Novartis, Pfizer, and Boehringer Ingelheim. And mapped 450+ TechBio x Drug Discovery in Europe. 🔎Most big pharma have placed between three to seven bets in Techbio. The most active pharma have been Merck, Sanofi and Bayer. The startups with the most partnerships/investments are Exscientia, BenevolentAI. What does a partnership deal look like usually? 💰In the case of partnerships with AI/computational drug discovery startups, the deal usually looks like this: upfront payment: $30M-60M performance/target-based payments: $500M-$2B Clearly, the upfront commitment for big pharma is not very demanding, and the big payout only happens if targeted outcomes are met. Are big pharma acquiring some of these startups? Mostly not. Partnerships and investments are the preferred route. However, notable exceptions exist, such as InstaDeep acquisition by BioNTech SE. Also notably, Thermo Fisher Scientific (US medical equipment maker) has acquired Olink Proteomics for $3.1B to expand its life sciences portfolio that helps drug discovery. Find out more in the full report by Dealroom.co and Speedinvest in the link below 👇 #techbio #drugdiscovery #bigpharma

Thoughts on this? >> After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech

Thoughts on this? >> After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #biotech #healthcare

In a recent interview with PharmaVoice, CEO Bill Newell provides insights into the critical evaluation of preclinical data and emphasizes the importance of an experienced and collaborative team. #PharmaVoice #pipeline #industryinsights #SutroBio $STRO

💰💊 Big Pharma has committed a staggering $5.5 billion to AI drug discovery partnerships this quarter so far. I've crafted a map showcasing AI Drug Discovery collaborations within the Top 20 Pharma (plus their subsidiaries) with their potential deal size (including milestones and royalties) to get a bird's-eye view of those choosing partnerships to bring in new AI capabilities to their discovery programs. With today's announcement of its $140 million collaboration with Series A company AQEMIA, we continue to see Sanofi push full steam ahead with its 'all-in' approach to adopting AI in every step of its pipeline, including discovery. With no signs that Pharma will be slowing down, who do you think will lead in AI adoption through partnerships in 2024? #PharmaInnovation #AIDrugDiscovery #FutureOfPharma #AIAdoption #BigPharmaAI #DrugDiscoveryRevolution #InvestingInAI #2024PharmaTrends #IndustryInsights Genentech NVIDIA BioMap Bayer Twist Bioscience AstraZeneca Absci AbbVie BigHat Biosciences IBM Boehringer Ingelheim Gilead Sciences Valo Health Amgen PostEra Eli Lilly and Company PRISM BioLab Co., Ltd., The Janssen Pharmaceutical Companies of Johnson & Johnson XtalPi Inc.

💊 Small Biotech Pioneers Surge in US Orphan Drugs Market, with Majors Like Amgen Expanding Through Acquisitions 🗞️ The Deets: The US orphan drugs market, dedicated to treating rare diseases, has seen dynamic growth, primarily driven by smaller biotechnology firms. Historically neglected due to profitability concerns, the landscape has shifted with FDA's support, leading to over 1000 orphan-designated drugs in trials. Notably, large pharma companies, such as Amgen, are entering the space by acquiring smaller innovators. 🗣️ My Two Cents: Small biotechs are nailing innovation for rare diseases, but big pharma's got the muscle to take it big. Just hoping that when these giants hop in, it's more about patients than just the cash. Could be a game-changer if they play it right … 🎤Your Turn: If smaller biotechs are the idea factories for orphan drugs, how can big pharma best amplify these innovations without dimming the original spark?

With a record high of 28 biopharma organizations filing for bankruptcy by October 2023, it was not a stellar year for the industry. There is often a huge gap between the promise of drug discovery research and the reality of bringing a promising therapy to commercialization. Because of this, we are seeing small to midsize biotechs increasingly partnering to facilitate biopharma development. This is an avenue that can change the life sciences landscape in 2024.

Navigating the drug launch journey requires biotech leaders to blend foresight with agility. Here are key tactics to keep your commercial phase on track, paving the way for a stellar market debut. https://lnkd.in/es3HTW8Y #DrugLaunch #DrugLaunchProcess #BioTechTrends #CompassConsulting

Sanofi, a leader in pharmaceutical innovation, is bolstering its AI-driven drug discovery with a significant $140M collaboration with Parisian startup Aqemia. This multi-year partnership aims to develop small molecules across various therapeutic areas. Aqemia's unique approach combines theoretical physics and generative AI, enabling efficient molecule design without the need for supercomputers. This deal marks Sanofi's sixth AI-focused venture since 2021, underscoring its strategy to lead in AI-powered pharmaceuticals. Aqemia, also thriving, plans to double its team by 2024 and establish spinoff companies for each molecule developed, showcasing a dynamic fusion of AI and biotech. #AIinPharma #Sanofi #InnovativeDrugDiscovery

💥 The Need for a Leaner, More Agile Biotech Ecosystem The pharmaceutical industry, boasting revenues over $1.3 trillion in 2020, is grappling with R&D inefficiencies. Often, even insiders lack clarity on their own R&D costs. The opaque nature of traditional R&D in big pharma makes efficiency comparisons challenging. A shift towards a more transparent, agile biotech system is essential. 🌟 Enter Vesper: our biotech venture is dedicated to fostering a nimble biotech ecosystem. We achieve this by integrating cutting-edge technologies, and collaborating with academic groups for deeper industry insights. By prioritizing innovation and agility, we're paving the way for a more efficient and responsive biotech future. #biotech #agility #Vesper https://lnkd.in/gsE7fEBM.